AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Non-small cell lung cancer with EGFR mutations are known to develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors show AURKB activation to be associated with resistance in EGFR mutant lung cancer cells, and that AURKB is a therapeutic target in resistant tumours that lack the p.T7...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, Jordi Codony-Servat, Ana Giménez-Capitán, Frédérique Cantero, Mike Burbridge, Sonia Rodríguez, Cristina Teixidó, Ruth Roman, Josep Castellví, Silvia García-Román, Carles Codony-Servat, Santiago Viteri, Andrés-Felipe Cardona, Niki Karachaliou, Rafael Rosell, Miguel-Angel Molina-Vila
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/34f8c0286b2b4c818818bdd02b7b3019
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/34f8c0286b2b4c818818bdd02b7b3019

Ejemplares similares